Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Urinary Tract Infections

Urinary Tract Infections

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Urinary Tract Infections

63 trials tracked for Urinary Tract Infections: 23 in phase 3 or 4 and 7 with published results. The most-cited published study has 136 citations.

63Trials tracked
23Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 9 Phase 3 14 Phase 2 13 Phase 1 5 Other / NA 22
  1. Phase 3 Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections Completed · 136 cited
  2. Phase 3 Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI) Completed · 100 cited
  3. Phase 3 A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI) Completed · 98 cited
  4. Phase 3 Corticosteroids for Children With Febrile Urinary Tract Infections Completed · 33 cited
  5. Phase 3 Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women Completed · 14 cited
  6. Phase 4 Effects of Antibiotic Prophylaxis on Recurrent UTI in Children Completed · 9 cited
Show 44 more trials
  1. Phase 3 Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures Completed · 9 cited
  2. Phase 4 A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects Completed
  3. Phase 4 A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL]) Completed
  4. Phase 4 Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection Completed
  5. Phase 4 Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults Completed
  6. Phase 4 Preventing Recurrent UTI With Vaginal Estrogen Completed
  7. Phase 4 A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections Completed
  8. Phase 4 Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI) Completed
  9. Phase 4 PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region Completed
  10. Phase 3 Prevention of Post-operative Urinary Retention Completed
  11. Phase 3 Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury Completed
  12. Phase 3 A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis) Completed
  13. Phase 3 A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis) Completed
  14. Phase 3 A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Completed
  15. Phase 3 Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055) Completed
  16. Phase 3 Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) Completed
  17. Phase 3 Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI) Completed
  18. Phase 2 Effectiveness of Preurodynamic With Posturodynamic Levofloxacin on the Incidence of UTI Completed
  19. Phase 2 Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion Completed
  20. Phase 2 Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy Completed
  21. Phase 2 Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Completed
  22. Phase 2 A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections Completed
  23. Phase 2 Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection Completed
  24. Phase 2 The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children" Completed
  25. Phase 2 Preventing Urinary Tract Infection Post-Surgery Completed
  26. Phase 2 Fecal Microbiota Transplantation (FMT) for MDRO UTI Completed
  27. Phase 2 Multifaceted Treatment of Catheter-related Urinary Tract Infection Completed
  28. Phase 2 Urinary Track Infection Prevention After Urogynecological Surgery Completed
  29. Phase 2 Effectiveness of Single Dose Fosfomycin and Single Dose Levofloxacin as Pre-urodynamic Antibiotic for UTI Prevention Completed
  30. Phase 2 Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003) Completed
  31. Phase 1 Colonizing Neurogenic Bladders With Benign Flora Completed
  32. Phase 1 Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections Completed
  33. Phase 1 Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study Completed
  34. Phase 1 Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants. Completed
  35. Phase 1 Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli Completed
  36. N/A Cefpodoxime vs Ciprofloxacin for Acute Cystitis Completed
  37. N/A Extended Spectrum Betalactamase Producing Bacteria; Epidemiology and Treatment in Non-hospitalized Patients Completed
  38. N/A Single Dose Monurol for Treatment of Acute Cystitis Completed
  39. N/A Cranberry for UTI Prevention in Residents of Long Term Care Facilities Completed
  40. N/A Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections Completed
  41. N/A Women's Improvement of Sexual Health (WISH) Demonstration Project Completed
  42. N/A Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Completed
  43. N/A Laser Therapy for Treatment of Urogenital Symptoms in Women Completed
  44. N/A A Biochip for Rapid Diagnosis of Complicated Urinary Tract Infection Completed

Showing the 50 most-cited and recently-updated of 63 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Urinary Tract Infections: what the trials found

Several pharmacological interventions have been evaluated for the management and prevention of urinary tract infections (UTIs). Gepotidacin was studied in multiple trials, showing significant therapeutic response at test-of-cure in one cohort (p=0.0003) 16, while another trial showed no statistically significant difference in therapeutic response between groups (p=0.1445) 17. In a separate study of Gepotidacin, 54.4% of participants achieved clinical symptom improvement at 24 hours, with varying rates of clinical symptom resolution across cohorts 3.

Antibiotic regimens including Doripenem, Cefepime/taniborbactam, and Sulopenem etzadroxil/probenecid were evaluated in various contexts. Cefepime/taniborbactam showed a statistically significant difference in composite success at test-of-cure (p=0.0088) 15. Doripenem was associated with varying rates of clinical response and documented outcomes regarding ICU readmission and hospital readmission [13, 14]. Sulopenem etzadroxil/probenecid was also utilized in a large-scale study 20.

Prophylactic measures and other agents include the use of antibiotic prophylaxis [5, 7], vaginal estradiol tablets 1, and vaginal scrubs prior to surgery 19. Gentamicin Sulfate demonstrated a statistically significant reduction in the number of UTIs over time (p=<0.0001) 22. Other evaluated treatments include Zavicefta (Ceftazidime-Avibactam) 8, nitrofurantoin monohydrate/macrocrystalline capsules [10, 12], Cefadroxil 11, and cystoscopic fluid containing Neosporin G. U. Irrigant 9.

Recent results — preliminary, needs further review

  • GSK3882347 was evaluated in a Phase 1 trial 4.
  • An antibiotic use report study observed various metrics for broad-spectrum and total antibiotic therapy per 1000 bed days of care 6.

For the clinician treating this condition

  • Gepotidacin shows significant therapeutic response in some clinical settings, though results regarding its efficacy compared to other treatments were not statistically significant in another trial.
  • Gentamicin Sulfate demonstrated a significant reduction in the frequency of UTIs over time (p=<0.0001).
  • Cefepime/taniborbactam showed statistically significant composite success at test-of-cure (p=0.0088).

AI synthesis of 13 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Periodontal inflammation may amplify genitourinary susceptibility in perimenopausal and postmenopausal women
Infectious Disease Sys. Review
Periodontal inflammation may amplify genitourinary susceptibility in perimenopausal and postmenopausal women Periodontal Inflammation May Increase Risk of Genitourinary Infections
This narrative review explores the link between periodontal inflammation and genitourinary susceptibility in perimenopausal and postmenopaus…
Gum health may play a surprising role in how women experience recurring urinary tract infections and other genitourinary issues.
Frontiers Oct 17, 2026
Oral fosfomycin noninferior to intravenous carbapenems for clinical cure in ESBL-producing Enterobacterales UTIs
Infectious Disease RCT
Oral fosfomycin noninferior to intravenous carbapenems for clinical cure in ESBL-producing Enterobacterales UTIs Oral fosfomycin shows promise for treating complicated urinary tract infections
This multicenter, open-label, randomized noninferiority trial evaluated 299 adults with complicated UTIs caused by ESBL-producing Enterobact…
Patients with complicated urinary tract infections may be able to switch from IV drugs to oral fosfomycin with similar success rates.
Oct 10, 2026
Shorter-course antibiotic therapy is comparable to longer-course for children with acute uncomplicated UTIs
Infectious Disease Meta-analysis
Shorter-course antibiotic therapy is comparable to longer-course for children with acute uncomplicated UTIs Shorter Antibiotic Courses May Work for Children with UTIs
This meta-analysis of 13 trials involving 2010 children found no significant difference in relapse, reinfection, bacteriological cure, or cl…
A review of data from over 2,000 children suggests that shorter antibiotic courses are as effective as longer ones for treating uncomplicate…
Oct 4, 2026
Renal and bladder ultrasonography shows limited sensitivity for detecting vesicoureteral reflux in pediatric patients
Pediatrics Meta-analysis
Renal and bladder ultrasonography shows limited sensitivity for detecting vesicoureteral reflux in pediatric patients Ultrasound tests show limited accuracy for detecting kidney reflux
This systematic review and meta-analysis of 90 studies evaluates the diagnostic accuracy of renal and bladder ultrasonography (RBU) for vesi…
Ultrasound scans may not be reliable enough on their own to detect a condition called vesicoureteral reflux in children with urinary tract i…
Oct 3, 2026
ASA score of 3 or higher is an independent risk factor for UTI in rectal cancer patients
Gastroenterology RCT
ASA score of 3 or higher is an independent risk factor for UTI in rectal cancer patients High surgical risk scores predict urinary infections in rectal cancer patients
This post-hoc analysis of a randomized clinical trial involved 208 male patients undergoing rectal cancer surgery. The study identified ASA …
A high ASA score, which measures a patient's overall health, is a key predictor of urinary tract infections after rectal cancer surgery.
Oct 2, 2026
Intravesical aminoglycoside instillations reduce recurrent urinary tract infection risk with an IRR of 0.23
Infectious Disease Meta-analysis
Intravesical aminoglycoside instillations reduce recurrent urinary tract infection risk with an IRR of 0.23 New findings show ways to reduce recurring urinary tract infections
This systematic review and meta-analysis of 25 studies evaluates intravesical instillations for preventing recurrent urinary tract infection…
Doctors are looking at new ways to stop repeat urinary tract infections using local treatments like aminoglycosides or hyaluronic acid.
Jul 25, 2026
Antibiotic prophylaxis reduces UTI risk in children with VUR but increases antibiotic resistance
Infectious Disease Meta-analysis
Antibiotic prophylaxis reduces UTI risk in children with VUR but increases antibiotic resistance Taking daily antibiotics lowers UTI risk but raises resistance chances for young patients with reflux
This systematic review and meta-analysis of 2577 children with vesicoureteral reflux found that continuous antibiotic prophylaxis reduced UT…
A large review found that daily antibiotics reduce urinary infections in kids with reflux. However, this treatment also makes bacteria harde…
Jun 5, 2026
Meta-analysis finds high fluoroquinolone resistance in E. coli causing UTIs globally
Infectious Disease Meta-analysis
Meta-analysis finds high fluoroquinolone resistance in E. coli causing UTIs globally 1 in 3 UTI E. coli cases now resist common antibiotics
This meta-analysis of 36 studies reports a pooled fluoroquinolone resistance prevalence of 31.09% in E. coli from UTIs. Resistance varied by…
A global review finds that nearly a third of E. coli from UTIs are resistant to key fluoroquinolone antibiotics, making infections harder to…
Frontiers May 25, 2026
Cefepime-nacubactam and aztreonam-nacubactam non-inferior for complicated UTI and pyelonephritis
Infectious Disease RCT
Cefepime-nacubactam and aztreonam-nacubactam non-inferior for complicated UTI and pyelonephritis New antibiotics show promise for complicated urinary tract infections
This phase 3 randomised double-blind study in adults with complicated urinary tract infection or acute uncomplicated pyelonephritis found ce…
A large trial found new antibiotic combinations worked better than standard care for certain urinary infections in adults.
May 16, 2026
Critical narrative review discusses barriers to implementing urinary tract infection diagnostics in clinical practice
Infectious Disease Sys. Review
Critical narrative review discusses barriers to implementing urinary tract infection diagnostics in clinical practice New tests for urinary tract infections could help fight antibiotic resistance
This critical narrative review addresses the challenges of integrating diagnostic innovations for urinary tract infections into frontline he…
A review finds that rapid diagnostic tests for UTIs could reduce unnecessary antibiotic use, but cost and policy barriers slow their adoptio…
Frontiers May 15, 2026
Nitrofurantoin outperforms single-dose fosfomycin for uncomplicated UTIs in Spanish primary care
Infectious Disease RCT
Nitrofurantoin outperforms single-dose fosfomycin for uncomplicated UTIs in Spanish primary care Nitrofurantoin beats single-dose fosfomycin for common bladder infections in women
This Phase 4 randomized clinical trial evaluated four antibiotic regimens in women with uncomplicated urinary tract infections in Spanish pr…
New research shows nitrofurantoin works better than single-dose fosfomycin for curing common bladder infections in women.
Apr 27, 2026
Review of ESBL-producing E. coli epidemiology and fluoroquinolone resistance in Mexican community isolates
Infectious Disease
Review of ESBL-producing E. coli epidemiology and fluoroquinolone resistance in Mexican community isolates UTIs Are Getting Harder to Treat — Here’s Why
This retrospective cross-sectional study reviews community-acquired E.
This could change how doctors choose antibiotics for UTIs.
medRxiv Apr 23, 2026

Questions about Urinary Tract Infections

Can a dipstick urinalysis reliably detect UTIs in babies under one year old?

Dipstick urinalysis has high specificity but low sensitivity for detecting UTIs in infants under 12 months, meaning it can rule in infection but often misses it.

Full answer →
How accurate is a dipstick test for UTI in febrile infants under 12 months?

A dipstick test is fairly accurate for UTI in febrile infants under 12 months, with high specificity (91-99%) but moderate sensitivity (60-90%), meaning it rules in infection well but may miss some cases.

Full answer →
What is the rate of breakthrough UTIs in children with VUR on antibiotics?

About 30.5% of children with VUR on antibiotic prophylaxis experience a breakthrough UTI, with higher risk in infants, high-grade reflux, and those with kidney scarring.

Full answer →
How common is fluoroquinolone resistance in community-acquired E. coli causing urinary tract infections in Mexico?

Fluoroquinolone resistance in community-acquired E. coli causing UTIs in Mexico is high, with studies showing up to 68% of isolates are ESBL-producing and associated with high resistance rates.

Full answer →
Does the FDA approved cefepime injection treat urinary tract infections in patients?

Yes, the FDA-approved cefepime injection is indicated for treating uncomplicated and complicated urinary tract infections caused by susceptible bacteria.

Full answer →
What is the global resistance rate for fluoroquinolones in E. coli causing urinary tract infections?

A 2025 meta-analysis found the global fluoroquinolone resistance rate in E. coli causing UTIs is about 31%, with ciprofloxacin resistance at 30%.

Full answer →
See all 6 questions about Urinary Tract Infections →

All Urinary Tract Infections Articles